Centessa’s stock recovers from drop on sleep drug data
Centessa Pharmaceuticals executives will be breathing a sigh of relief as its stock price recovered after a drop caused by …
Post
-
-
MoonLake claws back HS potential for sonelokimab on teen trial results
MoonLake Therapeutics’ sonelokimab has posted a potential comeback in hidradenitis suppurativa (HS) following the positive results of a Phase III …
-
MMI wins IDE for surgical robotic Alzheimer’s disease study
US-based robotics company Medical Microinstruments (MMI) has obtained an investigational device exemption (IDE) from the US Food and Drug Administration …
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by the …
-
Kodiak reports follow-up outcomes from APEX study of KSI-101
Kodiak Sciences has announced follow-up outcomes from the APEX study, which showed sustained clinical effect of KSI-101 through week 20 …
-
CERo commences second cohort of AML trial
CERo Therapeutics has initiated the second cohort of its Phase I clinical trial of CER-1236 for the treatment of acute …
-
Clinical Trials Arena Excellence Awards 2025: Phesi
Phesi, a patient-centric clinical data science company serving the global biopharmaceutical industry, won the Innovation award in the 2025 Clinical …
-
Spinogenix’s ALS hopeful to advance to registrational trial
Spinogenix is progressing its lead candidate, SPG302, to a registrational trial following the positive outcome of its mid-stage study in …
-
Kamada enrols first subject in Cytogam trial for CMV infection
Kamada has enrolled the first participant in an investigator-initiated clinical trial of Cytogam (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) to …
-
Valneva announces positive data for VLA1601 in Phase I trial
Valneva has reported encouraging results from a Phase I clinical trial assessing the immunogenicity and safety of its second generation …
-
Chiesi drops COPD and asthma asset after Phase III miss
Chiesi Group has dropped its late-stage clinical programme for its chronic obstructive pulmonary disease (COPD) and asthma candidate, tanimilast. This comes …
-
Sydnexis unveils more data for SYD-101 days after FDA refusal
Sydnexis has revealed further data of its paediatric progressive myopia (PPM) candidate, which met both the primary and secondary endpoints, …
-
Therapeutic Radiopharmaceuticals: Download 2025 Global Report
Key insights include: Precision oncology advances driving radiopharmaceutical innovation and adoption. Rising global trial activity and early-phase development. Strong market momentum with growing …
-
Two of Sarepta’s DMD drugs fail to meet primary endpoint in confirmatory trial
Two of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) candidates have failed to reach their primary endpoint in a Phase III …
-
Vir Biotechnology concludes Eclipse 1 Phase III trial enrolment for CHD
Vir Biotechnology has concluded subject enrolment for the Phase III Eclipse 1 trial assessing the efficacy and safety of tobevibart …
